GLP-1R agonists like as liraglutide are currently widely used in the clinic as second-line therapy for type II diabetes, and GLP-1R agonists have been used in the clinical treatment of obesity in countries such as Korea and the United States (3, 4, 5). Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.